Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.


Clinical Trial Description

Phase 1, multi-center, open-label, dose-escalation study to: - Evaluate the safety profile and MTD of RP-6306 when administered orally to establish the recommended Phase 2 dose and schedule - Characterize the PK and pharmacodynamics of RP-6306 monotherapy - Assess preliminary anti-tumor activity associated with RP-6306 monotherapy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04855656
Study type Interventional
Source Repare Therapeutics
Contact Peter Manley, MD
Phone 857-322-5553
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date April 2021
Completion date June 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1
Active, not recruiting NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04592653 - A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment Phase 2
Active, not recruiting NCT03704246 - Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors Phase 2
Recruiting NCT04478461 - Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT04237805 - A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients Phase 1/Phase 2
Recruiting NCT04135261 - A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors Phase 1
Completed NCT01387321 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies Phase 1
Completed NCT01453387 - MSC2015103B in Solid Tumors Phase 1
Recruiting NCT04805307 - Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 Phase 1
Recruiting NCT04049903 - Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1
Recruiting NCT04592484 - A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors Phase 1/Phase 2
Recruiting NCT03466268 - Study to Evaluate the Safety and Anti-tumor Activity of SCC244 Phase 1
Recruiting NCT03666273 - A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Phase 1
Completed NCT03272256 - Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma Phase 1